-
Clinical Trials & Development3 days agoVitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial
Researchers found that the vitamin B5 derivative pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine...
-
Clinical Trials & Development3 days agoEMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
In a Phase 1 study, treatment with Incyte's KRAS G12D inhibitor in combination with standard-of-care chemotherapy elicited an 89% confirmed objective response rate in patients with...
-
Clinical Trials & Development3 days agoNovartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
-
Clinical Trials & Development3 days agoOpinion: Cancer vaccines are finally here. How do we get them to patients?
“If we want cancer vaccines to reach patients faster than BRCA testing did, there are several challenges to address now,” write Karen E. Knudsen and Othman...
-
Clinical Trials & Development3 days agoSacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
RAHWAY, N.J.--(BUSINESS WIRE) October 26, 2026 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of...
-
Clinical Trials & Development4 days ago
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE) October 26, 2026 -- SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced...
-
Clinical Trials & Development4 days agoESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the...
-
Clinical Trials & Development4 days agoSTAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial...
-
Clinical Trials & Development4 days agoESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda
JNJ-6143, which came from Johnson & Johnson’s $3 billion takeover of Halda Therapeutics in 2025, showed a 75% overall response rate in the Phase 1 readout.
-
Clinical Trials & Development4 days agoESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
